Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy.

Couzi, Rima; Helzlsouer, Kathy J.; Fetting, John H.

doi:10.1200/jco.1995.13.11.2737

Cited by 277 publications

(205 citation statements)

References 35 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…In addition, while the literature on risk factors for insomnia in breast cancer remains relatively new [4], there are data suggesting the importance of vasomotor symptoms vis-a`-vis insomnia in studies of breast cancer [8,54] and menopausal women in general [38][39][40][41][42][43]. Vasomotor symptoms are well-established sequelae of the climacteric, whether natural or treatment induced.…”

Section: Discussionmentioning

confidence: 99%

“…Insomnia affects approximately 20% of adults in the general population and is more common in cancer patients [1] (prevalence estimates in cancer range from 23−61% [2][3][4][5]) and may be particularly common in women who have undergone treatment for breast cancer [6,7]. For example, a recent report found that of women who had completed treatment for breast cancer reported non-specific sleep problems [3,7], 19% met criteria for insomnia syndrome which was chronic in 95% of cases [3,7], and 23−44% reported insomnia 2−6 years after receiving their breast cancer diagnosis [8,9]. Despite its elevated prevalence and potential impact on quality of life (QOL) [4,7,10,11] insomnia in cancer has only recently begun to receive attention and little is known about risk factors for insomnia in this population [4].…”

Section: Introductionmentioning

confidence: 99%

“…stage [3,52], treatment [3,11]), physical health/symptoms (e.g. physical health [10,14,53], pain [52,53], vasomotor symptoms [8,54], GU symptoms [11]), fatigue [53,55,56], light exposure [57], and other variables identified as linked with insomnia in the general population (e.g. being widowed/separated [3], lower education [52], poor social support [52], depression/psychological distress [52,53]).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The relative importance of specific risk factors for insomnia in women treated for early‐stage breast cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The relative importance of specific risk factors for insomnia in women treated for early‐stage breast cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Approximately 25%-50% of all prescriptions written for patients with cancer are for hypnotics [7,8]. Additionally, sleep disruptions can persist in cancer survivors for many years after diagnosis and completion of treatment, making it one of the most pervasive problems faced by patients with cancer [9,10].…”

Section: Thementioning

confidence: 99%

Cancer-Related Fatigue and Sleep Disorders

et al. 2007

View full text Add to dashboard Cite

Sleep disorders, such as difficulty falling asleep, problems maintaining sleep, poor sleep efficiency, early awakening, and excessive daytime sleepiness, are prevalent in patients with cancer. Such problems can become chronic in some patients, persisting for many months or years after completion of cancer therapy. For patients with cancer, sleep is potentially affected by a variety of factors, including the biochemical changes associated with the process of neoplastic growth and anticancer treatments, and symptoms that frequently accompany cancer, such as pain, fatigue, and depression.Fatigue is highly prevalent and persistent in patients with cancer and cancer survivors. Although cancerrelated fatigue and cancer-related sleep disorders are distinct, a strong interrelationship exists between these symptoms, and a strong possibility exists that they may be reciprocally related. The majority of studies that have assessed both sleep and fatigue in patients with cancer provide evidence supporting a strong correlation between cancer-related fatigue and various sleep parameters, including poor sleep quality, disrupted initiation and maintenance of sleep, nighttime awakening, restless sleep, and excessive daytime sleepiness. This paper reviews the data from these studies with a view toward suggesting further research that could advance our scientific understanding both of potential interrelationships between sleep disturbance and cancer-related fatigue and of clinical interventions to help with both fatigue and sleep disturbance. The Oncologist 2007;12(suppl 1): [35][36][37][38][39][40][41][42]

show abstract

“…T he use of estrogen and estrogen-progesterone combinations for hormone replacement therapy (HRT) is becoming increasingly common among women, mainly for the alleviation of menopausal symptoms 1 and the prevention of osteoporosis. [2][3][4][5] Although reports on the efficacy of HRT to treat coronary heart disease are mixed, 6 -8 it is used for the long-term prevention of coronary heart disease in women.…”

mentioning

confidence: 99%

Hormone replacement therapy and breast carcinoma risk in Hispanic and non‐Hispanic women

Gilliland

Baumgartner

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDHormone replacement therapy (HRT) alleviates menopausal symptoms and prevents osteoporosis, but there is concern that long‐term use may have an adverse impact on breast carcinoma risk. Epidemiologic studies report inconsistent findings regarding the relationship between HRT and postmenopausal breast carcinoma risk and there is little information on the HRT‐associated risk among minority women.METHODSTo investigate the effects of HRT on breast carcinoma risk among Hispanic women, we examined data from the New Mexico Women's Health Study (NMWHS), a statewide case–control study comprising 366 postmenopausal women with breast carcinoma and 403 controls. Conditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence intervals (95% CI).RESULTSAfter adjustment for sociodemographic, medical, and reproductive factors, we found an increased risk associated with long‐term users of estrogen replacement therapy (ERT; OR for ERT use longer than 140 months was 2.57, 95%CI, 1.25–5.28, compared with ERT use shorter than 17 months). In addition, there was a positive trend with the duration of ERT use (P < 0.01). Hispanic postmenopausal women appeared to be at a significantly greater risk than non‐Hispanic white women (OR for ERT use longer than 140 months in Hispanics was 5.53, 95%CI, 1.47–20.87; OR in non‐Hispanics was 2.65, 95%CI, 0.95–7.34, compared with ERT use shorter than 17 months). In contrast, no significant association was observed for combined estrogen‐progesterone use in either Hispanic or non‐Hispanic women.CONCLUSIONSThe results of this study indicated that postmenopausal women had significantly increased breast carcinoma risk for long‐term ERT use. The risks among Hispanic women were substantially higher than among non‐Hispanic white women although they were not statistically significant. Cancer 2002;95:960–8. © 2002 American Cancer Society.DOI 10.1002/cncr.10791

show abstract

Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy.

Abstract: Vasomotor symptoms have a significant impact on the quality of life of breast cancer patients. Clinical trials to determine the safest and the most effective ways to relieve these symptoms are needed.

Cited by 277 publications

References 35 publications

The relative importance of specific risk factors for insomnia in women treated for early‐stage breast cancer

The relative importance of specific risk factors for insomnia in women treated for early‐stage breast cancer

Cancer-Related Fatigue and Sleep Disorders

Hormone replacement therapy and breast carcinoma risk in Hispanic and non‐Hispanic women

Contact Info

Product

Resources

About